研報掘金丨天風證券:君實生物加速後期管線研發,維持“買入”評級
天風證券研報指出,君實生物(688180.SH)加速後期管線研發,強化核心產品持續發力。據悉,昂戈瑞西單抗的上市申請已被NMPA受理,涵蓋適應症包括原發性高膽固醇血癥(雜合子型家族性和非家族性)以及混合型血脂異常,還包括用於成人或12歲以上青少年的純合子型家族性高膽固醇血癥。此外,FIC在研藥物tifcemalimab已獲准進行國際多中心Ⅲ期臨牀研究,這是BTLA靶點藥物首個確證性研究。該行考慮到公司三季度財務數據以及後續放量預期,該行將公司2023至2025的預期營業收入由20.40億、29.24億、37.40億調整為15.02億、25.91億、37.96億元人民幣,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.